CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoque, A.
Right arrow Articles by Lippman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoque, A.
Right arrow Articles by Lippman, S. M.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 587-590, June 2002
© 2002 American Association for Cancer Research

Short Communication

HER-2/neu Gene Amplification in Ductal Carcinoma In Situ of the Breast1

Ashraful Hoque, Nour Sneige, Aysegul A. Sahin, David G. Menter, James W. Bacus, Gabriel N. Hortobagyi and Scott M. Lippman2

Departments of Clinical Cancer Prevention [A. H., D. G. M., S. M. L.], Pathology [A. A. S., N. S.], and Breast Medical Oncology [G. N. H.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Bacus Laboratories Inc., Lombard, Illinois 60148 [J. W. B.]

This study evaluated the relative frequencies of HER-2/neu gene amplificationin ductal carcinoma in situ (DCIS)-associated invasive breast cancer and DCIS alone. We examined archival tissue samples of 100 DCIS lesions with an invasive component (cases) and 100 without an invasive component (controls), with cases and controls matched by pathologic nuclear grade. HER-2/neu gene amplification was determined by fluorescence in situ hybridization. We compared HER-2/neu gene amplification in DCIS lesions only, irrespective of the presence or absence of an invasive component. HER-2/neu gene amplification occurred significantly less frequently in the cases (26%) than in the controls (40%), with an odds ratio of 0.35 (95% confidence interval, 0.17–0.72; P < 0.004) after adjustment for pathologic and quantitative-image-analyzed morphometric nuclear grade. The HER-2/neu gene also was amplified more frequently in higher- than in lower-grade DCIS alone (56% versus 19%, respectively; P < 0.0001) or in higher- than in lower-grade DCIS with invasive cancer (44% versus 2%, respectively; P < 0.00001). Future studies should examine the potential roles of HER-2/neu and other biomarkers (e.g., p21 and Rb) as markers of the risk of DCIS patients for invasive breast cancer and as molecular targets of chemoprevention in breast intraepithelial neoplasia.




This article has been cited by other articles:


Home page
 JCOHome page
J. M.S. Bartlett, I. O. Ellis, M. Dowsett, E. A. Mallon, D. A. Cameron, S. Johnston, E. Hall, R. A'Hern, C. Peckitt, J. M. Bliss, et al.
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4423 - 4430.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. M. Ip, S. O. McGee, P. A. Masso-Welch, C. Ip, X. Meng, L. Ou, and S. F. Shoemaker
The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium
Carcinogenesis, June 1, 2007; 28(6): 1269 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu
Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene
J Natl Cancer Inst, November 2, 2005; 97(21): 1611 - 1615.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Ewer and S. M. Lippman
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
J. Clin. Oncol., May 1, 2005; 23(13): 2900 - 2902.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, R. Colomer, and R. Lupu
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification
Ann. Onc., March 1, 2005; 16(3): 359 - 371.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M Lacroix, R-A Toillon, and G Leclercq
Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics
Endocr. Relat. Cancer, September 1, 2004; 11(3): 497 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Lippman and W. K. Hong
Cancer Prevention Science and Practice
Cancer Res., September 15, 2002; 62(18): 5119 - 5125.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.